AstraZenca has entered into a settlement agreement with Accord Health and Intas Pharmaceuticals to prevent the sale of generic copies of its anti-psychotic drug Seroquel XR in the US.
The company has granted Accord a licence to enter the US market with its version of the drug on November 1 2016, or earlier, depending upon certain circumstances.
Go deeper with GlobalData
The news follows last week’s announcement that AZ had won its fight to prevent Handa Pharmaceuticals from entering the market with its copy of the extended-release pill for the treatment of schizophrenia until 2016.
The news does not resolve patent battles with other generic drugmakers.
Seroquel will lose patent protection next year but AZ is trying to switch patients over to the newer version (Seroquel XR) ahead of the arrival of generic forms of basic Seroquel.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
